Analgesic effect of GT-0198, a structurally novel glycine transporter 2 inhibitor, in a mouse model of neuropathic pain.

@article{Omori2015AnalgesicEO,
  title={Analgesic effect of GT-0198, a structurally novel glycine transporter 2 inhibitor, in a mouse model of neuropathic pain.},
  author={Yumiko Omori and Mayumi Nakajima and Kazumi Nishimura and Eiki Takahashi and Tadamasa Arai and Masato Akahira and Tomohiko Suzuki and Mie Kainoh},
  journal={Journal of pharmacological sciences},
  year={2015},
  volume={127 3},
  pages={
          377-81
        }
}
This study was conducted to identify the characteristic pharmacological features of GT-0198 that is phenoxymethylbenzamide derivatives. GT-0198 inhibited the function of glycine transporter 2 (GlyT2) in human GlyT2-expressing HEK293 cells and did not bind various major transporters or receptors of neurotransmitters in a competitive manner. Thus, GT-0198 is considered to be a comparatively selective GlyT2 inhibitor. Intravenous, oral, and intrathecal injections of GT-0198 decreased the pain… 
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
TLDR
It is demonstrated that 33 provides greater analgesia at lower doses, and does not possess the severe side effects of the very slowly reversible GlyT2 inhibitor, ORG25543 (2).
Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain.
TLDR
Oral administration of this GlyT 2 inhibitor evoked partial pain relief in PCIBP rats and did not evoke central nervous system side effects in contrast to GlyT2 inhibitors reported by others.
Glycine transporter inhibitors: A new avenue for managing neuropathic pain
TLDR
This paper overviews inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain, and suggests that drugs inhibiting both GlyT-1 and Glyt-2 non-selectively and reversibly, may favorably target neuropathicPain.
Glycine receptors and glycine transporters: targets for novel analgesics?
Glycinergic neurotransmission has long been known for its role in spinal motor control. During the last two decades, additional functions have become increasingly recognized—among them is a critical
Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model
TLDR
To the best of the knowledge for the first time, augmented analgesia is demonstrated by combining GlyT-1 and 2 inhibitors and increased CSF glycine content supports involvement of glycinergic system in neuropathic pain.
Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling
TLDR
The therapeutic potential of GlyT inhibitors as a novel class of analgesics is highlighted, recent advances reported for the field are presented, and the key challenges associated with the development of a GlyT inhibitor into a safe and effective agent to treat pain are discussed.
Discovery of GlyT2 Inhibitors Using Structure-Based Pharmacophore Screening and Selectivity Studies by FEP+ Calculations.
TLDR
A new set of promising hits are discovered that inhibit the glycine transporter at nano- and micromolar activity and have excellent selectivity over GlyT1 (as shown by in vitro studies) using a newly designed virtual screening protocol that combines a structure-based pharmacophore and docking screens with a success rate of 75%.
Glycinergic transmission: glycine transporter GlyT2 in neuronal pathologies
TLDR
Recent advances in understanding the role of GlyT2 in the pathophysiology of inhibitory glycinergic neurotransmission are reviewed, with a focus on the areas of caudal areas of the nervous system and pain transmission.
Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia
TLDR
Reciprocal regulation of dopamine and glycine in forebrain, glycine modulation of glutamate, Glyine signaling interaction with postsynaptic density proteins at glutamatergic synapse, and human genetics of glycinergic pathways in SCZ are tackled in order to highlight the exploitation of this neurotransmitters and related molecules.
Modulation of Glycine-Mediated Spinal Neurotransmission for the Treatment of Chronic Pain.
  • C. Cioffi
  • Chemistry, Medicine
    Journal of medicinal chemistry
  • 2018
TLDR
This Perspective highlights the potential that pharmacotherapies capable of increasing inhibitory spinal glycinergic neurotransmission hold in providing new and transformative analgesic therapies for the treatment of chronic pain.
...
1
2
...

References

SHOWING 1-10 OF 37 REFERENCES
Spinal Antiallodynia Action of Glycine Transporter Inhibitors in Neuropathic Pain Models in Mice
TLDR
GlyTs were established as the target molecules for the development of medicaments for neuropathic pain after it was demonstrated that i.v. or intrathecal administration of GlyT1 inhibitors, or knockdown of spinal GlyTs by small interfering RNA of GlyTs mRNA produced a profound antiallodynia effect in a partial peripheral nerve ligation model and other neuropathicPain models in mice.
Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats.
TLDR
GlyT2 plays a major role in the clearance of extracellular glycine in the spinal cord and that GlyT2 inhibition leads to amelioration of CYP-induced bladder overactivity and pain behavior, and may be a novel therapeutic target for the treatment of overactive bladder and/or bladder hypersensitive disorders such as bladder pain syndrome/interstitial cystitis.
The Antinociceptive Effect of Intrathecal Administration of Glycine Transporter-2 Inhibitor ALX1393 in a Rat Acute Pain Model
TLDR
The findings suggest that the inhibitory neurotransmitter transporters are promising targets for the treatment of acute pain and that the selective inhibitor of GlyT2 could be a novel therapeutic drug.
Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain
TLDR
It is indicated that inhibition of glycine transporters is capable of evoking significant effects on nociceptive behavior in neuropathic pain and whether glycine transporter inhibitors have the capability to gain clinical relevance as analgesic compounds on the long run has to be elucidated in further investigations.
Glycine Transporter Inhibitors as a Potential Therapeutic Strategy for Chronic Pain with Memory Impairment
TLDR
An increase in endogenous glycine via glycine transporter 1 blockade not only results in a net inhibitory influence on pain transmission at the spinal level but also supraspinally relieves decreased synaptic efficacy presumably related to cognitive disturbance often described in patients with chronic pain.
Positive N-methyl-d-aspartate receptor modulation by selective glycine transporter-1 inhibition in the rat dorsal spinal cord in vivo
TLDR
Evidence is provided that the observed increased inextracellular citrulline is a consequence of positive modulation of NMDA-R, secondary to increased extracellular glycine and support a protective role for GlyT-1 against fluctuations in extrace cellular glycine uptake at glutamatergic synapses in the dorsal spinal cord.
Structure, function and regulation of glycine neurotransporters.
TLDR
This review deals on recent progress on localization, transport mechanisms, structure, regulation and pharmacology of the glycine transporters (GLYTs).
GlyR α3: An Essential Target for Spinal PGE2-Mediated Inflammatory Pain Sensitization
TLDR
It is demonstrated that inhibition of a specific glycine receptor subtype (GlyR α3) by PGE2-induced receptor phosphorylation underlies central inflammatory pain sensitization and may provide a previously unrecognized molecular target in pain therapy.
Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain.
TLDR
The results suggest that GlyT2 is a potential target for treatment of dynamic and static allodynia in patients with herpes zoster and postherpetic neuralgia and the lack of efficacy of GlyT1 inhibitor may be explained by activation of NMDA receptors and the down-regulation ofglyT1 in the lumbar dorsal horn.
Reduction in Thermal Hyperalgesia by Intrathecal Administration of Glycine and Related Compounds
TLDR
It is proposed that glycine administered intrathecally reduces the pain response evoked by the hotplate analgesia meter method, and may operate primarily through the NMDA receptor complex.
...
1
2
3
4
...